CellAction collaboration signed with Institut Curie

CellAction, the immunotherapy acceleration platform at Institut Curie, entered a research collaboration with Neotis.

The programme validates transmembrane targets directly in IPF patient biopsies by multiplex immunofluorescence, and tests antibodies generated with external CROs against those targets.

The first work package, establishing in vitro models of senescence and the accompanying analytical tools, has since reported, with subsequent packages extending into patient tissue.